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Colorectal cancer (CRC) is the second most common cause of cancer death. 
Molecular events in CRC has been extensively studied and several data 
suggest that Wnt/β-catenin signaling deregulation play a pivotal role in 
colorectal carcinogenesis. Majority of both familial syndromes (FAP) and 
sporadic colon cancers, arise from APC or β-catenin genes alterations, leading 
to Wnt signaling hyperactivation. According to the cancer stem cells (CSCs) 
theory, some cancer-initiating cells, harboring stem-cell like properties, evade 
standard chemotherapies, resulting in recurrent and metastatic tumors. Wnt/β-
catenin signaling and its deregulation is involved in the recurrence and 
maintenance of CSCs. In recent years, understanding of molecular 
mechanisms underlying CSCs biology, led to development of novel strategies 
to completely eradicate colorectal cancer. 
Some evidences suggest a potential crosstalk between the endocannabinoid 
system and the Wnt pathway, also in cancer stem cells, in several tumor types. 
This could represent a key mechanism in the control of the anti-cancer activity 
of cannabinoids, as well as a novel putative site for pharmacological 
intervention.  
Results from this work led to identification of Rimonabant, originally an 
inverse agonist of CB1 cannabinoids receptor, as modulator of Wnt/β-catenin 
pathway in CRC, able to control colon cancer stemness, without toxicity 
toward cells from healty tissue. Moreover, for the first time, we proposed a 


























Colorectal cancer (CRC) development is typically associated with a 
stepwise accumulation of specific genetic alterations, collectively known as 
“adenoma-carcinoma sequence”. This multistep process drives the onset of 
pathologic alterations, ranging from microscopic lesions, such as Aberrant 
Crypt Foci (ACF), to metastatic phenotypes. However, in the last decades, 
better understanding of cancer genetic features, needed to improve colon 
cancer management, highlighted that adenoma-carcinoma sequence arises in a 
limited portion of CRC cases (about 50-60%). To date, seems to be clear that 
an higher genetic complexity exists, which results in elevated heterogeneity, 
both at inter- and intra-tumoral level (Fearon, 2011; Punt et al, 2016). 
It was widely accepted that the majority of both familial syndromes 
(Familial Adenomatous Polyposis, FAP) and sporadic colon cancers, arise 
from inactivation of APC (Adenomatous Polyposis Coli) tumor suppressor 
gene that negatively regulates Wnt/β-Catenin pathway. APC truncation results 
in loss of β-Catenin-binding domain, thereby into failure of β-Catenin 
degradation. With high frequency, CRC with wild type APC, harbor gain of 
function mutation in β-Catenin gene, typically associated with loss of 
phosphorylation sites, required for its proteasomal degradation. This alteration 
seems to be related to high malignant CRC. Substantially, both APC and β-
Catenin genes mutations, allow to hyperactivation of Wnt signaling (Deitrick 







Wnt/β-Catenin pathway is an highly conserved signaling, known to exerts a 
key role not only in embryonic development and normal tissue homeostasis, 
but also in the most part of cancer-related processes, such as proliferation, 
differentiation, apoptosis, and cell survival (Anastas & Moon, 2013). Tissue- 
and contest-specific, Wnt pathway consists of ligands and receptors that 
orchestrate an intricate signal transduction. Wnt ligands family includes about 
19 members for about 10 Frizzled receptors. The signaling across plasma 
membrane can be transduced through canonical pathway (β-Catenin-
dependent) and non-canonical pathway (β-Catenin-independent). In canonical 
signaling, the absence of Wnt ligands culminates with constitutive β-Catenin 
degradation. A multiprotein cytoplasmic complex consisting of casein kinase 
1α (CK1α), Axin, glycogen synthase kinase 3 (GSK3) and APC, promotes β-
Catenin phosphorylation, tag for its ubiquitination and proteasomal 
degradation. Canonical ligands, such as Wnt3, bind Frizzled (Fzd) receptor 
and low density Lipo protein Receptor-related Protein 5 (LRP5) or LRP6 co-
receptor to phosphorylate Dishvelled (Dvl3) protein. This latter, sequestering 
GSK3 and Axin, leads to disruption of degradation complex, thereby blocking 
the degradation of β-Catenin. Once accumulated in cytoplasm, β-Catenin 
translocates in the nucleus where displaces Groucho transcriptional repressor 
and binds Lymphoid Enhancer-binding Factor (LEF) and T Cell Factor (TCF) 
proteins (Deitrick & Pruitt, 2016; Anastas & Moon, 2013). This culminates 
with transcriptional activation of downstream target genes. Some of Wnt-
regulated genes, such as COX-2, c-Myc, Cyclin D1, CD44 and Lgr5 are 
critically involved in colorectal carcinogenesis (Herbst et al, 2014).  
Non-canonical β-Catenin-independent signaling, can be transduced through 
two mainly ways: Planar Cell Polarity (PCP) pathway and Wnt/Ca2+ pathway, 
mediated by protein kinase C (PKC) and calcium/calmodulin-dependent 
protein kinase II (CaMKII) (Anastas & Moon, 2013). Of note, it was reported 







Wnt3-induced pathway. Moreover, with high frequency, Wnt5 promoter 
results methylated in human CRC cell lines and in human primary tumors, 
suggesting its potential as epigenetic biomarker or therapeutic target for CRC 
(Mikels & Nusse, 2006; Ying et al, 2008). 
In addition to TCF/LEF transcription factor, β-Catenin nuclear activity 
downstream canonical signaling, includes binding with several other proteins. 
The complex transcriptional machinery regulated by β-Catenin on Wnt 
Responsive Elements (WRE), includes among others p300 (Kat3b) and 
CREB-binding protein (CBP or Kat3a) co-activators. p300 and CBP are two 
high-related proteins, able to coordinate chromatin remodeling complex 
through their histone lysine acetyltransferases (HAT) catalytic activity 
(Mosimann et al, 2009). Despite their high homology, CBP and p300 seem to 
play a non-redundant role in cell proliferation and differentiation, but several 
reports demonstrated that both CBP-selective (ICG-001 and PRI-724) and 
CBP/p300 non-selective (C646) inhibitors are able to exert their antitumor 
effects in CRC, counteracting β-Catenin binding and transcriptional activity on 
WRE (Bordonaro & Lazarova, 2016; Gaddis et al, 2015).  
Although alterations in Wnt/β-Catenin signaling players were found in the 
most of CRC, it is now clear that only Cancer Stem Cells (CSCs), Wnt 
hyperactive subset of cells within tumor bulk, retain tumorigenic ability, 
supporting hierarchical organization of CRC. Self-renewal, loss of 
differentiation, high resistance to a large part of chemotherapeutics and iper-
expression of specific markers (such as c-Myc, CD133, CD44, Lgr5) are 
typical features of CSCs. It’s widely accepted that in high malignancy, 
chemoresistance and thus relapses onset are certainly ascribable to cancer stem 
cells (Zeuner et al, 2014; Todaro et al, 2010; Vermeulen et al, 2010; O'Brien et 
al, 2007). In recent years, understanding of molecular mechanisms underlying 
CSCs biology, led to development of novel strategies to completely eradicate 







To date, several compounds able to target Wnt pathway in CRC and other 
tumors, have been identified, including cannabinoids. DeMorrow and 
colleagues, in 2008 reported that anandamide (AEA), a cannabinoid receptor 1 
(CB1) agonist, inhibits cholangiocarcinoma growth through activation of the 
non-canonical Wnt pathway. In addition, a stable analogue of endogenous 
anandamide (Met-F-AEA) inhibits β-Catenin transcriptional activity in human 
breast cancer cells, repressing TCF/LEF promoter activation (Laezza et al, 
2010). More interesting, some reports demonstrated the ability of cannabinoids 
to inhibit gliomagenesis targeting glioma stem cells (GSCs) (Aguado et al, 
2007; Nabissi et al, 2015) and inhibit spheroid formation in prostate cancer 
stem cells (Sharma et al, 2014). 
Antitumor action of cannabinoids in CRC, was strongly supported by 
several authors. The Endocannabinoid (EC) system role in the progression of 
colorectal cancer has been analyzed in vivo (Izzo AA et al., 2008; Santoro et 
al, 2009) were cannabinoids-mediated reduction of precancerous lesions in the 
mouse colon was found. In CRC cells, with different mechanisms, both CB1 
and CB2 agonist, as well as antagonists showed antitumor action, inducing cell 
death mechanisms ranging from apoptosis to mitotic catastrophe (Greenhough 
et al, 2007; Cianchi F et al, 2008; Izzo AA et al, 2008; Santoro et al, 2009). 
Intriguingly, Proto and colleagues, in 2012, demonstrated that in colon cancer 
cells cannabinoids modulate CB1 and estrogen receptors (ERs), whose loss 
might promote and accelerate colorectal carcinogenesis in APCMin/+ mice 
(Proto et al, 2012; Wang et al, 2008). Finally, cannabinoids improve the 
efficacy of chemotherapic drugs used in the clinical practice (Gustafsson et al, 
2009; Gazzerro et al, 2010).  
Here, for the first time, we investigated in vitro and in vivo the hypothesis 
that the antitumor effects of cannabinoids in CRC could be due to direct 
modulation of Wnt/β-Catenin pathway. Moreover, cannabinoids effects on 























2.1 General materials. 
Rimonabant (also referred as SR141716 or SR) was kindly donated by 
Sanofi-Aventis (Montpellier, France). It was dissolved in DMSO and added to 
cells cultures at the indicated concentrations. 2-Methyl-2'-Fluoro Anandamide 
(Met-F-AEA), 5-Fluorouracil and Oxaliplatin were purchased from Sigma-
Aldrich (Dorset, UK). CB13 and CB74 were synthetized and kindly donated 
by Prof. Clementina Manera (Dept. of Pharmacy, University of Pisa) (fig. 1).  
 
Figure 1. Chemical structures of cannabinoid compounds. 
 
Anti-caspase-3 and cleaved caspase 3, anti-PARP [poly (ADP-ribose) 
polymerase], anti-GAPDH, anti-phospho--Catenin, anti-Wnt3, anti-LRP6, 
anti-phospho-GSK3Ser, anti-GSK3, anti-CaMKII, anti-c-Myc and anti-
COX-2 antibodies were all from Cell Signaling Technology (Danvers, MA, 
USA); anti--Catenin, anti-Dvl3, anti-Fzd7, anti-APC, anti-Wnt5A, anti-
ROR2, anti-phospho-CaMKII, anti-Lgr5, anti-acetyl histone H3 and anti-
acetyl histone H4 were from Abcam (Cambridge, UK). Anti-Cyclin D1 and 
 
 




anti-Lamin A/C were purchased and Sigma-Aldrich (Dorset, UK), 
respectively. Secondary HRP-linked goat anti-mouse or goat anti-rabbit IgG, 
were also purchased from Cell Signaling Technology (Danvers, MA, USA). 
Anti-Annexin V-FITC, anti-CD133-PE, anti-CD44-FITC were from Miltenyi 
biotec.  
 
2.2 Cell cultures, treatments and viability assay.  
Human CRC cells DLD1, SW620, SW48 and HCT116 were obtained from 
the Interlab Cell Line Collection (IST, Genoa, Italy). DLD1 cells were 
routinely grown in RPMI-1640, SW620 cells in Dulbecco’s modified Eagle 
medium (DMEM), SW48 in DMEM-F12 and HCT116 cells in McCoy's 5A 
medium, supplemented with 10% fetal bovine serum (FBS), 1% non-essential 
amino acids, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
in monolayer culture and incubated at 37˚C in a humidified atmosphere 
containing 5% CO2. Cells were exposed to various concentrations of 
compounds for the times showed in the figures and to evaluate cells viability 
the colorimetric MTT metabolic activity assay was used. To this aim, MTT 
stock solution (5 mg/ml in PBS, Sigma) was added to each well and incubated 
for 4 h at 37˚C in humidified CO2. At the end of the incubation, the medium 
was removed and the formazan crystals were solubilized with acidic 
isopropanol (0.1 N HCl in absolute isopropanol). MTT conversion to 
formazan by metabolically viable cells was monitored by spectrophotometer at 
an optical density of 570 nm. Each data point represents the average of three 
separate experiments in triplicate.  
 
2.3 Cell cycle and FACS analysis. 
To assess cell cycle profiles, HCT116 cells (2,5x104/6cm plate) were 
treated for 24 and 48h with Rimonabant 10µM or vehicle alone. At the end of 
treatments they were collected, fixed in 70% ethanol and kept at -20 °C 
 
 




overnight. Propidium iodide (PI; 50 µg/ml) in ice-cold phosphate-buffered 
saline (PBS) was added to the cells for 15 min at room temperature. The cells 
were acquired by a FACS-Calibur flow cytometer (BD Biosciences). Analysis 
was performed with ModFit LT v3.2 (Verity Software House). 
For FACS analysis of apoptosis induction, HCT116 cells were double 
stained with FITC-conjugated Annexin V (BioLegend) in a binding buffer (10 
mM HEPES/NaOH, pH 7; 140 mM NaCl; 2.5 mM CaCl2) for 20 min at room 
temperature and then with PI for additional 15 min in the dark. The cells were 
analyzed on a FACS-Calibur flow cytometer (BDIS, Becton Dickinson). FITC 
and propidium iodide emissions were detected in the FL-1 and FL-2 channels, 
respectively. For each sample, at least 20000 cells were recorded and 
subsequent analysis was performed with FlowJo® software (BDIS). 
 
2.4 Western blot analysis. 
Total protein extracts were obtained through lysis in buffer A (50 mM Tris–
HCl pH8.0 buffer containing 150 mM NaCl, 1% Nonidet P-40, 2 mg/ml 
aprotinin, 1 mg/ml pepstatin, 2 mg/ml leupeptin, 1 mM Na3VO4). Protein 
concentration was determined by the Bradford assay using bovine serum 
albumin as standard. 10-30 µg of proteins were loaded were subjected to 8-12 
% SDS-PAGE, under reducing conditions. Gels were electroblotted into 
nitrocellulose membranes (Millipore Co) and filters were probed with the 
primary antibodies indicated in general materials.  
Subcellular fractionation of cytoplasmic and nuclear protein extracts was 
obtained by using NE-PER® Nuclear and Cytoplasmic Extraction Reagents 
(Thermo scientific). Immunoreactive bands were quantified with Image Lab 










2.5 Luciferase assay. 
HCT116 cells were transiently cotransfected with an inducible transcription 
factor-responsive construct encodes the Firefly luciferase reporter gene under 
the control of a basal promoter element (TATA box) containing tandem 
repeats of TCF/LEF Response Element (TRE). To normalize transcription 
efficiency a constitutively expressing Renilla construct encoding the Renilla 
luciferase reporter gene under the control of a CMV immediate early 
enhancer/promoter was used. As negative control we used non-inducible 
reporter construct encodes firefly luciferase under the control of a basal 
promoter element (TATA box), without any additional transcriptional 
response elements. Finally, to evaluate transcription efficiency, constitutively 
expressing GFP construct was used. All constructs were purchased from 
Quiagen and used according to manufacturer’s protocol. Mixture of above 
described constructs was distributed as shown in figure 2. Transcription  
efficiency was calculated as percentage of GFP expressing cells versus total 
cells (mean of cellular counts performed in at least 5 microphotographs from 4 
independent experiments). Luciferase activity was measured using a dual 
luciferase assay system (Promega), according to manufacturer’s instruction 









and read with an EnSpire-2300 luminometer (Perkin Elmer). Relative firefly 
luciferase activity was obtained by normalizing it to that of Renilla luciferase 
activity. 
 
2.6 Confocal microscopy. 
Cells were grown on slides in 12 well plates (3 x 104 cells/well). After 
treatment, cells were fixed in parafolmadehyde (PFA, 3,7% v/v in PBS) for 15 
minutes, washed and permeabilized in Tryton X-100 (0,1% v/v in PBS) for 10 
minutes. Then, cells were blocked with 4% Bovine Serum Albumin (BSA) for 
1 h at room temperature and incubated with anti-β-Catenin (ab32572 Abcam; 
1:250) and Anti Lamin A/C (SAB4200236 Sigma-Aldrich; 1:250) primary 
antibody, at 4° C overnight. Immunofluorescence staining was obtained by 
incubating for 90 minutes with Alexa Fluor® 488 donkey anti-rabbit IgG 
(A21206, Molecular Probes®; 2 µg/ml) and Alexa Fluor® 594 goat anti-
mouse IgG (A11032, Molecular Probes®; 1 µg/ml) secondary antibodies. The 
slides were mounted using mowiol mounting medium; a Zeiss LSM 510 Laser 
Scanning Microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) for 
data acquisition was used. Samples were vertically scanned from the bottom of 
the coverslip with a total depth of 5 μm and a Plan-Apochromat oil-immersion 
objective (magnification 63X*1.7; 1.40 NA). A total of 10 z-line scans with a 
step distance of 0.5 μm were collected and single planes or maximum-intensity 
z-projection of stacks and an orthogonal projection (=xy, xz, yz planes for z-
stacks series) were generated with Zeiss LSM Image Examiner Confocal 
Software (Carl Zeiss MicroImaging GmbH). 
 
2.7 Semiquantitative RT-PCR. 
Total RNA extraction, cDNA synthesis and reverse-transcription PCR were 
performed as described in Proto et al, 2012. The specific primer pairs used for  
 
 




β-Catenin gene were: F 5’-GTCCGCATGGAAGAAATAGTTGA-3’, R 5’-
AGCTGGTCAGCTCAACTGAAAG-3’ 
All reactions were performed at least in triplicate; the PCR products were 
quantified with Image Lab analysis software (Bio-Rad) and results were 
normalized to those obtained from ActinB.  
 
2.8 Drug combination analysis. 
The relative contribution of Rimonabant and 5-FU to the anti-proliferative 
effect in HCT116 cells and establishment of pharmacological interaction type, 
were calculated using Compusyn, dedicated software based on Chou-Talalay 
method (Chou & Talalay, 1984). Through median-effect equation, that is the 
common-link for single and multiple ligand interactions, this software allow 
calculation of Combination Index (CI) to define synergism (CI<1), additive 
effect (CI=1) and antagonism (CI>1). Moreover, Dose reduction index (DRI) 
representing the measure of how much the dose of each drug in a combination 
may be reduced at a given effect level compared with the doses of each drug 
alone (Chou, 2010). Assessment of drug interactions was performed 
calculating CI after treatment for 24h with 1:2.5 Rimonabant/5-FU in 
combination and as single drugs. The treatments were performed at least in 
triplicate, in three independent experiments.  
 
2.9 Inverse Virtual Screening. 
The chemical structures of investigated compounds (SR141716, plus 30 
“blank” compounds) were built with Maestro (version 10.2, Schrödinger, 
LLC, New York, NY, 2015) Build Panel. Prior to perform molecular docking 
calculations, optimizations (Conjugate Gradient, 0.05 Å convergence 
threshold) of the structures were applied to identify possible three-dimensional 
models. Then, all the structures were converted in the .pdbqt format using 
 
 




OpenBabel software (version 2.3.2) (O'Boyle et al, 2011), adding Gasteiger 
charges.  
306 protein 3D structures were prepared downloading the .pdb files from 
the Protein Data Bank database (www.rcsb.org). For each structure, “non-
structural” water molecules were removed, and the processed file was then 
converted in .pdbqt format, merging non polar hydrogens and adding 
Gasteiger charges.  
Molecular docking calculations were performed using the Autodock-Vina 
software (Trott & Olson, 2010). In the configuration files linked to 3D 
structures of the protein, coordinates and dimensions along x,y,z axes of the 
grid related to the site of presumable pharmacological interest, with spacing of 
1.0 Å between the grid points. The exhaustiveness value was set to 64, saving 
10 conformations as maximum number of binding modes. For all the 
investigated compounds, all open-chain bonds were treated as active torsional 
bonds. 
A first set of promising interacting proteins of SR141716 was selected 
setting a predicted binding affinity cutoff = -7.5 kcal/mol. The identified 
proteins (166 items) were then also screened against “blank” molecules, the 
latter needed for the normalization (Lauro et al, 2012; Lauro et al, 2011) of the 
binding affinities of SR141716, as reported in equation 1: 
 
V=V0/VR [eq. 1] 
 
where, for each target investigated, V represents the normalized value of 
SR141716, V0 is its predicted binding affinity from docking calculations 
(kcal/mol), VR is the average value of binding energy calculated on all the 
“blanks” (kcal/mol). It is important to note that V is a dimensionless number, 
and then it can be used to predict the interacting targets of a case-study 
compound, rather than to have precise indications about the related binding 
 
 




affinities. After the normalization process, a final ranking was obtained from 
the most to the less promising target. Normalized values and predicted binding 
energies for SR141716 are collected in Table S2 (Supporting Information), 
respectively. The ligand/protein complexes were visually inspected with 
Maestro (version 10.2). Illustrations of the 3D models were generated using 
Maestro (version 10.2). 
 
2.10 Kat3B/p300 activity assay. 
To evaluate Rimonabant effects on intrinsic acetyltransferase activity of 
p300, fluorimetric cell-free assay was performed with recombinant p300 in the 
presence of SR141716, AVE1625 (Drinabant, another selective CB1 receptor 
inhibitor), anacardic acid (used as inhibitor control) or vehicle alone. Histone 
H3 peptide and Acetyl CoA were used as acetylation substrates and the 
fluorescence amplified by a thiol detecting probe was measured at Ex/Em = 
392/482 nm with an EnSpire 2300 multimode plate reader. Measurements 
were performed in triplicate for each treatment, and the experiment was 
repeated at least three independent times. 
Histone extracts from HCT116, DLD1 and SW48 cell lines treated with 
SR141716 (10μM) or with the vehicle alone were quantified for histone H3 
and histone H4 global acetylation with a colorimetric assay. Global acetylation 
status of histones H3 and H4 were also detected through western blot analysis 
of total protein extracts. 
 
2.11  In vivo studies. 
Animals. 20 female SCID mice (SHO, 6-8 weeks old) were obtained from 
Charles River, maintained under clean room conditions in sterile filter top 
cages with Alpha-Dri bedding and housed on high-efficiency particulate air 
(HEPA)-filtered ventilated racks. Animals received sterile rodent chow and 
water ad libitum. All experimental procedures were conducted in accordance 
 
 




with the Institute for Laboratory Animal Research Guide for the Care and Use 
of Laboratory Animals. The experimental protocols received the approval of 
the Ethical Committee of the Italian Board of Health (prot. n. 0031993 and n. 
0031994, June, 6, 2013). 
Subcutaneous xenograft models in athymic mice. HCT116 cells (1 x 106, 
suspended in 150 l of PBS) were implanted subcutaneously into the right 
flank region of each mouse and allowed to grow to the size of approximately 
50-70 mm3. SR141716 (0,07 mg/kg/dose in 150 l of PBS/20% Glycerol) was 
administered three time a week by peri-tumoral injection for 6 weeks. Animals 
in the corresponding control group received PBS/20% Glycerol (150 l) peri-
tumoral injected on the same schedule as SR141716. Mice were daily 
monitored for clinical signs and mortality. Body weight recordings were 
carried out bi- or three-weekly. Progress of tumors was determined by two 
dimensional caliper measurements, and tumor volumes were calculated using 
a standard hemi ellipsoid formula: [length (mm) x width (mm)2]/2. Tumor 
volumes were analyzed using one-way ANOVA. At the end of the study, mice 
were humanely euthanized and tumors were resected and frozen immediately 
or fixed in 10% formalin for further analysis. 
For western blot analysis, frozen tumor pieces were disrupted for protein 
extraction by gentle homogenization (Potter-Elvehjem Pestle) in cold RIPA 
buffer. About 30 µg of proteins was loaded on 12% SDS–polyacrylamide gels 
under reducing conditions and used for western blot analysis. For 
immunofluorescence staining and confocal analysis, fixed tumor pieces were 
OCT-embedded, sectioned (10 m), stained with primary and secondary 
antibodies (diluted in PBS/1% BSA/0,05% Triton-X-100) and analyzed using 









2.12  GTG7 cultures. 
Primary Colorectal Cancer Stem Cell line, GTG7, was kindly provided by 
Prof. Jan Paul Medema (Academisch Medisch Centrum (AMC), Center for 
Experimental and Molecular Medicine (CEMM), Laboratory of Experimental 
Oncology and Radiobiology (LEXOR), University of Amsterdam), obtained 
from patients as described in Prasetyanti et al (2013). GTG7 cells were 
cultured and propagated as spheroids in ultra-low adherent supports, in CSC 
medium (Advanced DMEM-F12) supplemented with: N2 supplement (Gibco), 
6mg/ml glucose, 5mM HEPES, 2mM L-glutamine, 4µg/ml heparin, 50ng/ml 
Epidermal Growth Factor (EGF) and 10ng/ml basic Fibroblast Growth Factor 
(bFGF). GTG7 spheroids, are established cells containing a TCF/LEF-driven 
GFP reporter for Wnt-signaling activity (Wnt-TOP-GFP), as described in 
Vermeulen et al (2010). In this system, the 10% highest expressing Wnt-GFP 
(TOP-GFPhigh or Wnthigh) represent CSCs, while the 10% lowest (TOP-GFPlow 
or Wntlow) identificate differentiated tumor cells.  
 
2.13  FACS-based Caspase 3 assay and Nicoletti assay. 
To measure cell death at single cell level in Wnthigh (CSCs) and at the same 
moment, in the same experiment, in Wntlow (differentiated colon cancer cells), 
cytofluorimetric analysis of caspase 3 activation was performed. GTG7 
spheroids were dissociated as single cells and seeded in triplicate, in 12 
multiwell plate (50000 cells/well) in adherent condition. After overnight 
adherence, cells were exposed to Rimonabant for 24 hours, at 5, 10, 15, 20 µM 
concentrations. At the end of treatments, GTG7 were collected as single cells 
using Trypsin-EDTA and washed with CSC medium. Caspase 3 activity was 
measured using CaspGlow active staining kit (Red-DEVD-FMK), according 
to manufacturer’s instructions (BioVision). Briefly, after collection and 
washing, cells were pelleted and stained with RED-DEVD-FMK substrate for 
1h at 37°C. Subsequently, cells were washed twice with wash buffer and flow 
 
 




cytometry was performed with FACS Canto (BD bioscience). Cell death was 
measured analysing PE intensity in 10% gated Wnt-GFPhigh and 10% Wnt-
GFPlow cells.  
To measure DNA fragmentation status, Nicoletty assay was performed. 
Cells were seeded and collected as described above, then resuspended in 
Nicoletti buffer (0.1% sodium citrate (w/v) and 0.1% Triton X‐100 (v/v) in 
deionized water pH 7.4, supplemented with 50 μg/ml propidium iodide before 
use). After incubation at 4°C, PI staining of nuclei was measured using flow 
cytometry (FACS Canto).  
Measurements were performed in triplicate for each treatment, and the 
experiment was repeated at least three independent times. Data were analysed 
with FlowJo® software (BDIS)  
 
2.14  Cell survival assay in GTG7. 
Spheroids cultures of CSCs were dissociated and seeded as single cells in 
12 multiwell plate (50000 cells/well). After overnight adherence, GTG7 were 
treated with Rimonabant as in cell death assay. At the end of treatments, they 
were collected after exposure with trypsin-EDTA and pelleted. For each 
treatment points, 20000 cells were distributed in triplicate in 96 ultalow 
adherent multiwell (Corning). Clones development, and then cell survival of 
CSCs, was measured at different time points, starting from day 0 
(corresponding to 24h treatments) until day 13, through colorimetric viability 
assay, by adding 20 µl/well of Cell Titer Blue (CTB) reagent (Promega). After 
4h of incubation, viability was monitored by spectrophotometer (560Ex/590Em 
nm). Each data point represents the average of three separate experiments in 










2.15  Normal colon human organoids cultures and clonogenic assay. 
Normal colon human organoids culture was kindly provided by Prof. Jan 
Paul Medema (AMC, University of Amsterdam), obtained as described in Sato 
et al (2011). The crypts were cultured in matrigel, in Normal colon culture 
medium: advanced DMEM/F12, supplemented with N2 and B27 supplement, 
Pen/Strep, gentamycin, amphotericin B, 2mM GlutaMax-1, 10mM HEPES, 
1mM N-acety-L-cysteine (Sigma), 10 nM [Leu15]-gastrin I (Sigma), 10mM 
nicotinamide (Sigma), 500nM A83-01 (Tocris), 3μM SB202190 (Sigma), 50% 
WNT3A conditioned medium, 50 ng/ml h-EGF, 20% RSPO1 conditioned 
medium, 10% Noggin conditioned medium, 10 nM PGE2 (Santa Cruz 
Biotechnology). 
For DNA fragmentation analysis, matrigel was mechanically destroyed and 
crypts were resuspended in Cell Recovery solution (BD bioscience). After 
incubation on ice, Nicoletti assay was performed as previously described in 
section 13.  
To assess Rimonabant effects on normal colon organoids clonogenicity, 50-
100 crypts were diluted in matrigel and seeded in 24 multiwell plate. After 
overnight incubation in normal colon medium, organoids were counted under 
microscope and then treated for 24h with Rimonabant 10, 15 and 20 µM. After 
treatments, matrigel was mechanically destroyed, organoids were collected 
and pelleted to remove Rimonabant. Then, for each replicate all organoids 
were diluted in new matrigel and seeded again in 12 multiwell plate, with 
fresh medium. After 7 days, vital crypts were counted under microscope. Each 
data point represents the average of two separate experiments in duplicate. 
 
2.16  Statistical analysis. 
Data obtained from multiple experiments were calculated as means ± SD 
and analyzed for statistical significance by using the 2-tailed Student t-test, 1- 
or 2-way ANOVA for independent groups, with the Tukey or Bonferroni 
 
 
























3.1 Cannabinoids-mediated control of human colorectal cancer cells in 
vitro. 
The ability to affect cell viability was initially screened for four 
cannabinoids compounds in human CRC cell line HCT116. In particular, 
CB13 and CB74, two synthetic CB2 receptor agonists, showed any activity on 
cell viability, at any of used concentrations. The synthetic analogue of 
endogen Anandamide, 2-Methyl-2'-Fluoro Anandamide (Met-F-AEA), CB1 
receptor agonist, was able to reduce significantly HCT116 cell viability after 
48h treatments, starting from 10 µM (fig. 3). The most promising results were 
obtained with CB1 antagonist/inverse agoinist Rimonabant (SR141716). A 
previous work from Santoro et al (2009) showed that in DLD1 and SW620 
CRC cell lines (β-Catenin wild type, APC mutant cells), Rimonabant is able to 
induce G2/M and S-G2/M arrest, respectively, without induction of apoptosis. 
In HCT116 cells (β-Catenin mutant cells) Rimonabant was able to inhibit cell 
growth significantly, starting from 24h treatments with 20 µM and from 5 µM 
after 48h treatments. Moreover, in HCT116 cells, a significant increase of 
Sub-G0/G1 cell phase, persistent until 48 hours, was observed after treatments 
with Rimonabant 10 µM (figure 4a). Cytofluorimetric analisys of PI/Annexin 
V-FITC double stained HCT116 cells, showed that Rimonabant induces an 
increase of double stained subpopulation (fig. 4b), suggesting a probable 
induction of apoptotic cell death. To confirm this hypothesis, western blot 









that Rimonabant induces PARP and Caspase-3 cleavage, starting from 24 h 
treatments whit 10 µM. To elucidate the precise cell death mechanism induced 
by Rimonabant, analysis of membranes from human apoptosis antibody array 
was performed. Obtained results, confirmed the data obtained with western 
blot and showed an upregulation of Cytochrome C and of several death 
receptors (TRAILR-1, -2 and -3). Finally, Rimonabant was able to 
downregulate antiapoptotic protein Bcl-2 and X-linked Inhibitor of Apoptosis 
Protein (XIAP) (figure 4c). 
To corroborate the results obtained in HCT116, another human CRC cell 
line was used. SW48 cells displays genetic profile similar to HCT116, 
arboring β-Catenin gene mutation and wild type APC and p53 genes. Similar 
to HCT116, MTT assay showed that Rimonabant significantly inhibits SW48 
cells growth, after 24h at 20 µM and starting from 10 µM after 48h of 
treatments. Furthermore, also in the line SW48 Rimonabant was able to 
activate PARP and Caspase 3 (fig. 4d).  
Figure 3. MTT assay in HCT116 cells treated with indicated doses of CB13, CB74, Met-F-
AEA and Rimonabant (SR141716). All experiments were performed in triplicate in at least 












Figure 4. a Cell cycle analysis of PI stained HCT116 cells treated with SR141716 (SR, 10µM). b 
FACS analysis of PI/anti-Annexin V-FITC double stained HCT116 cells untreated or treated for 
48 hours with SR141716 (SR, 10µM). c upper, representative western blot analysis of caspase 3 
and PARP (total and cleaved forms) expression in total protein lysates from HCT116 cells; lower, 
representative proteomic membrane of Human Apoptosis Antibody Array and relative 
densitometric analysis performed on total protein lysates from HCT116 treated for 48h with SR 
10µM. d upper, representative western blot analysis of caspase 3 and PARP (total and cleaved 
forms) expression in total protein lysates from SW48 cells; lower, MTT assay in SW48 cells 
treated with indicated doses of SR141716. All experiments were performed in triplicate in at least 









3.2 Cannabinoids inhibit Wnt reporter activity in HCT116 cells. 
The downstream effect of Wnt canonical (β-Catenin-dependent) signaling 
activation culminates with β-Catenin nuclear translocation, where it regulates 
TCF/LEF transcription factor on target genes promoters. Thus, to evaluate if 
Met-F-AEA and Rimonabant make -Catenin unable to activate the 
transcription of Wnt-regulated genes, analysis of the activation status of 
reporter genes containing TCF/LEF binding sites was performed through 
luciferase assay, in HCT116 cells. To evaluate the efficiency of transient 
transfection, we firstly analyze GFP reporter expression used as positive 
control. A percentage of about 70% of cells expressing GFP was obtained, 
indicating a correct and efficient transfection (fig. 5a). Afterwards, in HCT116 
cells, luciferase activity was measured through transiently transfection with 
the reporter containing the TRE for TCF/LEF. As shown in figure 2b, 
treatments for 24h with Met-F-AEA 10 µM produced only a slight reduction 
of luciferase activity (about 23%). However, at same time, Rimonabant (10 
µM) significantly reduces luciferase activity of about 50% (fig. 5b), showing a 
more promising activity than Met-F-AEA in Wnt signaling inhibition.  
 
3.3 Rimonabant affects β-Catenin transcriptional activity and sub-
cellular localization in HCT116 cells. 
The ability of Rimonabant to affects -Catenin activity was validated 
analyzing its expression and sub-cellular localization. Immunofluorescence 
staining of HCT116 cells treated with Rimonabant 10 µM, clearly showed that 
-Catenin protein expression results significantly reduced starting from 24h of 
treatments. Furthermore, analysis of orthogonal projections performed through 
confocal microscopy, confirm that reduction of -Catenin transcriptional 
activity, could be due to Rimonabant-mediated inhibition of nuclear 











Western blot analysis of fractionated cytoplasmic and nuclear protein 
extract corroborate reduced expression and nuclear localization of -Catenin, 
starting from 24h of treatments (fig. 7a). β-Catenin mRNA levels were also 
reduced by Rimonabant at the same time points (fig. 7b). 
As previously described, nuclear translocation of β-Catenin is due to the 
failure of its degradation in the cytosol. Indeed, β-Catenin destabilization is 
usually performed by degradation complex containing APC, Axin, CK1 and 
GSK3-β proteins. The latter two, catalyze β-Catenin phosphorylation on Ser45 
and Thr41/Ser37/Ser33 respectively, all tags for proteasome-mediated 
degradation (Stamos & Weis, 2013). Rimonabant results able to significantly 
Figure 5. a Upper panel: Fluorescence microphotographs of HCT116 cells transfected with 
a constitutively expressing GFP reporter construct, used as positive control in the luciferase 
assays (magnification 10x). Lower panel: efficiency of the transfection procedure was 
calculated as percentage of green cells versus total cells (mean of cellular counts performed 
in at least 5 microphotographs from 4 independent experiments)  b Luciferase activity in 
extracts from HCT116 cells transfected with reporter construct containing the TRE for 
TCF/LEF (TCF/LEF response element) for 16 hours and treated with SR141716 or Met-F-
AEA 10µM or vehicle. The level of luciferase activity was taken as an arbitrary unit. The 
data are representative of at least three independent experiments where each sample was 









induce β-Catenin phosphorylation of Ser33/Ser37 residues, starting from 8h 
and until 48h of treatment with 10 µM (fig. 7c), suggesting that Rimonabant- 
 
mediated direct inhibition of canonical Wnt pathway, could be ascribable to β-
Catenin destabilization. 
TCF/LEF activation downstream Wnt signaling, lead to transcription of 
specific target genes. Among others, Cyclin D1, c-Myc and COX-2 play a key 
role in colorectal carcinogenesis (Herbst et al., 2014). Then, in order to 
Figure 6. After treatment with SR141716 (SR, 10 µM), HCT116 cells were fixed and 
stained with anti β-Catenin antibody (green fluorescence) to evaluate subcellular 
localization. Nuclei were stained with anti Lamin A/C antibody (red fluorescence). In 
right panels orthogonal view of 0.5 µm thickness in the z plane was reported. The data 









confirm canonical Wnt/-Catenin inactivation, analysis of protein expression 
of above cited genes was performed through western blot. As shown in figure 
3d, in HCT116 cell line, Rimonabant was able to reduce Cyclin D1, c-Myc 
and COX-2 expression, at the same time points in which a reduction of 




Figure 7. a Western blot analysis of β-Catenin expression in nuclear and cytoplasmic 
fractionated extracts from HCT116 cells. Cytoplasmic and nuclear amount of β-Catenin 
were normalized versus GAPDH and Lamin A/C respectively. b mRNA levels of β-
Catenin in HCT116 cells. c upper, representative western blot and densitometric 
analyses of β-Catenin (total and phosphorylated form) expression in HCT116 cells. 
Lower, the histograms shown represent the densitometric analyses of phospho-β-Catenin 
expressed as fold change of the total β-Catenin amount and normalized versus GAPDH. 
d Western blot analysis of Cyclin D1, c-Myc and COX-2 protein levels in HCT116 
cells. GAPDH was used as loading control. The data are representative of at least three 
independent experiments where each sample was analyzed in triplicate (mean±SD; 









3.4 Genotype dependence of Rimonabant-mediated Wnt/β-Catenin 
pathway regulation. 
To establish if Rimonabant effects represents a common mechanism in 
CRC, different cell lines with different genotype, were used. In particular, 
SW48 cells shows a genetic profile similar to HCT116, carrying β-Catenin 
gene mutation, APC and p53 wild type genes. Moreover, like HCT116 they 
present chemoresistant phenotype. Instead, DLD1 and SW620 cell lines do not 
carry mutations in β-Catenin gene, but are APC and p53 mutant. In addition, 
they are more sensitive to chemotherapeutics (Data obtained from Colon 
Cancer Atlas).  
First, β-Catenin phosphorylation status was examined. Western blot 
analysis of total extracts after treatments with Rimonabant 10 µM, showed that 
the strongest and persistent induction of phosphorylation occurs in SW48, β-
Catenin mutated cells, starting from 8h and until 48h of treatments. In DLD1 
and SW620 β-Catenin phosphorylation induction, was only slight and not 
Figure 8. Representative western blot and densitometric analysis of β-Catenin (total and 
phosphorylated form) expression in DLD1, SW48 and SW620 cells treated with SR141716 
(SR, 10µM). The histograms shown represent the densitometric analyses of phospho-β-
Catenin expressed as fold change of the total β-Catenin amount and normalized versus 









persistent, compared to β-Catenin mutant cells HCT116 and SW48 (fig. 8).  
In canonical pathway (β-Catenin-dependent), interaction of Wnt3 ligand, 
with Fzd7 receptors and the Wnt co-receptor LRP6 activates the Dishevelled 
(Dvl3) cytoplasmic phospho proteins, which inhibit the degradation complex 
consisting of CK1, Axin, APC and GSK3-β, thereby blocking the degradation 
of β-Catenin and then promoting its nuclear translocation (Anastas & Moon, 
2013; Kimelman & Xu, 2006). In HCT116 and SW48 β-Catenin mutant cells, 
we analyzed the influence of Rimonabant on canonical, β-Catenin-dependent 
pathway transduction. As shown in western blot panel in figure 5a, both in 
HCT116 and SW48 cells, the expression of Fzd7 receptor and LRP6 co-
receptor were reduced markedly, starting from 24h of treatment with 
Rimonabant, until 48h. Wnt3 ligand and Dvl3 expression, instead, was 
reduced starting from 24h for HCT116 and from 8h of treatment in SW48. 
GSK3-β activity can be inhibited by Akt-mediated phosphorylation at Ser9 
(Jacobs et al, 2012). We observed that Rimonabant induced the 
phosphorylation of GSK3β until 24h in HCT116 and until 48 hours of 
treatment only in SW48. Finally, a persistent increase of APC levels, were 
observed only in HCT116 cells (fig. 9a). Substantially, the above described 
results suggests that in β-Catenin mutant cells Rimonabant is able to directly 
inhibit canonical signaling across the plasma membrane. 
In addition to canonical pathway, Wnt signaling can be transduced through 
a non-canonical β-Catenin-dependent pathway. The activation of this pathway 
is triggered by distinct ligands and receptors than canonical way. Among 
others, Wnt5 is the best know ligand able to activate non-canonical pathway. 
Wnt5 results frequently downregulated in CRC cells (as in HCT116, SW48 
and SW620) due to its promoter methylation (Ying et al, 2008). Wnt5 interacts 
with ROR2 tyrosine kinase receptor activating actin-binding protein, filamin 









addition, the non-canonical pathway triggers intracellular calcium flux, 





canonical pathway and triggers the β-Catenin degradation or the inhibition of 
TCF/LEF-mediated transcription (Ishitani et al, 2003). To dissect the effect of 
Rimonabant on non-canonical pathway, western blot analysis was performed. 
Figure 9. Western blot analysis of protein levels in total lysates from in HCT116 
and SW48 cells treated with SR at indicated time points: a, canonical pathway: 
Wnt3, Dvl3, Fzd7, LRP6, GSK3β (total and phosphorylated form) and APC b, non-
canonical pathway: Wnt5A, ROR2 and CAMKII (total and active form). Blots are 









Rimonabant results able to activate non-canonical pathway, increasing Wnt5 
protein levels, Ror2 expression and activation of CaMKII only in HCT116 
cells, but not in SW48, after 8h treatments (fig. 9b).  
Subsequently, expression of Wnt target genes has been analyzed. 
Surprisingly, in all the in vitro models used, the expression trend of Cyclin D1, 
c-Myc and COX-2 were similar: starting from 8h of treatments and until 48h, 
a reduction in protein expression of Wnt-regulated genes was found in both β-
Catenin mutant (HCT116 and SW48) and wild type (DLD1 and SW620) cells 
(fig. 7d and 10). 
Overall, these findings indicate that also in cells were a direct inhibition of 
canonical pathway was not particular evident (DLD1 and SW620), 
Rimonabant is able to inhibits downstream Wnt-regulated gene products. This 
Figure 10. Representative Western blot of Wnt target Cyclin D1, c-Myc and COX-
2 protein expression, from SW48, DLD1 and SW620 cells. Blots are representative 









allow us to hypothesize that an indirect common mechanism mediated by 
Rimonabant, probably at transcriptional level, leads to downstream inhibition 
of Wnt signaling. 
 
3.5 p300 is potential binding site for Rimonabant. 
To clarify Rimonabant molecular mechanism and then to identify factors 
potentially able to interact with SR141716, we performed an in silico Inverse 
Virtual Screening testing the case-study compound on a panel of 306 proteins 
involved in cancer and inflammation events. Briefly, this computational tool 
allows the analysis of different binding hypotheses between a single ligand 
and a high number of targets through molecular docking experiments, 
determining the selection of the most promising ligand−receptor favorite 
complexes after a normalization of the predicted binding affinities, and 
successfully directing the subsequent biological assays (Lauro et al, 2012; 
Lauro et al, 2011).  
Among the obtained results, we were intrigued by p300 target at the 3
rd
 
position in the final ranking of predicted most affine proteins of SR141716. 
Specifically, the careful analysis of the sampled docking poses showed a 
good accommodation of SR141716 in the p300 binding site (PDB code 
3BIY), supporting the potential inhibition of the HAT activity exerted by the 
investigated compound. We found two interesting binding modes in which 
SR141716 is placed in p300 occupying the Ligand Binding Site (LBD) and 
exerting both polar and hydrophobic interactions. The analysis of the first 
pose, associated to the best docking score (ΔGbind=-11.2 kcal/mol), disclosed 
the arrangement of SR141716 in the deep part of the LBD supported by an 
edge-to-face π-π interaction between the pyrazole core and the indole moiety 
in the side chain of Trp1466, and an H-bond with the carbonyl oxygen in the 
backbone of Leu1398 (fig. 11a). Further polar interactions were established 









hydrophobic contacts with Tyr1414, Leu1463, Trp1466, Tyr1467 (fig. 11a, 
c). Another interesting binding mode (ΔGbind=-10.8 kcal/mol) showed the 
placement of the molecule in a more external part of the binding site, 
supported by halogen bonds between the dichloro-phenyl part of SR141716 
and Arg1410 (fig. 11b), while the edge-to-face π- π interaction between the 







Figure 11. a 3D docking models of SR141716 (colored by atom types: C green, O red, N 
blue, polar H light gray, Cl dark green) in the binding site of p300 (secondary structure 
depicted in orange ribbons) and c associated 2D interaction panel; b alternative 3D docking 
models of SR141716 and d associated 2D interaction panel. Residues in the active site are 
represented in sticks (colored by atom types: C grey, N blue, O red, S yellow, H light gray). 
H-bonds ligand/protein interactions are represented in green dotted lines, while π-π 









3.6 Rimonabant inhibits p300 histone acetyltransferase activity. 
Results from Inverse virtual screening, strengthened our previous 
hypothesis of Rimonabant-mediated transcriptional regulation. C-terminal 
domain of β-Catenin interacts, in the nucleus, with various chromatin 
remodelling protein. Among others, p300 and CBP Histone Acetyl 
Transferases (HATs) interact with β-Catenin and TCF transcription factor on 
Wnt-Response Elements (WRE). This interaction activates transcription of 
several Wnt/β-Catenin target genes, due to intrinsic HAT activity of 
p300/CBP, which results in rapid acetylation of histone H3 and H4 
(Bordonaro & Lazarova, 2016; Mosiman et al, 2009).  
Since Inverse Virtual Screening assay identificate p300 catalytic domain as 
specific binding site for Rimonabant, we evaluated p300 HAT activity through 
fluorimetric cell-free assay. Using anacardic acid (12,5 µM) as positive 
control, we asses assay efficiency. In a dose-dependent manner, starting from 
5 µM, Rimonabant results able to significantly reduce histone H3 acetylation 
as reflected by Coenzime A-SH (CoA-SH) reduced production and then 
reduced fluorescence emission (fig. 12).  
 
Figure 12. a Kat3B/p300 
histone acetyltransferase 
activity fluorimetric assay 
performed with recombinant 
p300 in the presence of 
SR141716, AVE1625, 
anacardic acid (used as inhibitor 
control) or vehicle alone. 
Results were expressed as 
means ± SD of 3 independent 
experiments performed in 
duplicate and reported as 
percentage vs the vehicle 










To verify if Rimonabant ability to reduce p300 HAT activity could be 
linked to CB1 receptor inhibition, we used in parallel another CB1-selective 
inhibitor, AVE1625 (also known as Drinabant). As shown in figure 12, 
AVE1625 was not able to reduce histone H3 acetylation, indicating that, even 
if further experiments are required, Rimonabant-mediated HAT inhibition 
could be CB1-indipendent mechanism.  
To confirm p300 HAT inhibition, analysis of global histone H3 and H4 
acetylation status, was performed using colorimetric assay on histone extracts 
from HCT116, DLD1 and SW48 treated with Rimonabant (10 µM) or vehicle 
alone, for indicated time points. In HCT116 cells both histone H3 and H4 
acetylation were strongly and significantly reduced starting from 4h of 
treatments with Rimonabant. In SW48 and DLD1, instead, only slight 
reduction of both modifications was found between 4h and 8h of treatments in 
DLD1 and after 6h of treatments in SW48 (fig. 13). Western blot analysis of 
protein total extracts substantially confirmed results obtained with colorimetric 
assay, showing a similar trend expression of acetylated histone H3 and H4 
















Figure 13, Left histograms, quantification of histone-H3 and histone-H4 total acetylation 
with a colorimetric assay in histone extracts from HCT116, SW48 and DLD1 cells treated 
with SR10µM; right panels, representative western blot analysis of histones extracts from 
HCT116, DLD1 and SW48 cells. Filters were probed with H4 acetylated (AcSer1, AcLys5-
8-12) or H3 acetylated (N-terminus) antibodies; Histone H3 were used as loading control. 
Panels are representative of 3 separate experiments. Results were expressed as means ± SD 
of 3 independent experiments performed in duplicate and reported as percentage vs the 









3.7 Rimonabant reduces CRC growth and Wnt/β-Catenin signaling in 
vivo.  
To evaluate in vivo Rimonabant efficacy, we also tested its effects in a 
subcutaneous (s.c.) HCT116 xenograft model. Tumor cell suspension was 
injected s.c. into 20 female SCID mice and when the tumor reached 
approximately the size of 50-70 mm
3
, 10 mice in the treated group received 
each the peri-tumoral injection of Rimonabant (0,07 mg/Kg/dose), while 10 
mice in the control group received vehicle alone. The tumor sizes have been 
recorded on the first day of Rimonabant treatment (day 0) and bi- or three-
weekly at the indicated time points. The intratumoral injections of the drug 
were then repeated three times a week for 6 weeks. All of the mice in vehicle 
(control) group developed tumors beyond 2,0 cm
3
 on average by day 42. In 
contrast, the mice in Rimonabant group developed much smaller tumors 
(figure 14a). In particular, by treatment day 42, ANOVA analysis indicates a 
significant smaller tumor size in treated group compared with animals in the 
control group (p<0.001) (figure 14b). 
Furthermore, after 42 days from treatment beginning, excised tumor 
sections were analyzed for -Catenin localization in cellular compartments 
through immunofluorescence staining with specific antibodies for -Catenin 
and for Lamin A/C (green and red fluorescence, respectively in figure 13c). 
The confocal microscopy demonstrated that in tissue sections from treated 
mice -Catenin localized mainly in the cytoplasm whereas nuclear staining 
was almost devoid of specific -Catenin signal (figure 14c). 
Finally, western blot analysis of total extracts from tissue specimens 
demonstrated that, despite the awaited tumor samples heterogeneity, the 
amount of p--Catenin, clearly detectable in the treated xenografts, was lost in 















Figure 14. a Representative growth of HCT116 xenograft in control (upper panel) and in 
treated groups (lower panel) at day 42. b Tumor volume growth curve after peri-tumoral 
injection of SR141716. Growth retardation by the compound was statistically significant 
for all time points labeled with * (p < 0.05) or with # (p<0,01). c Immunofluorescence 
staining of HCT116 xenografts tumor sections (10µm) performed for Lamin A/C (red 
fluorescence) and β-Catenin (green fluorescence) localization. Data are representative of at 
least three sections from each control and treated tissue sample. d Western blot analysis of 
total and phosphorylated β-Catenin (left panel), Cyclin D1 and c-Myc (right panel) in total 
lysate from resected tumor tissues. Results are representative of at least four samples 









3.8 Rimonabant control cancer stemness and chemoresistance in HCT116 
cells.  
A growing number of evidence, indicates that Wnt hyperactivity is closely 
related to stem-like phenotype and a large numbers of markers helps in the 
identification, isolation and targeting of CSCs (Kemper et al, 2010; Vermeulen 
et al, 2010).  
Our results, showed that Rimonabant is able to inhibit Wnt signaling. To 
establish if this compound can control cancer stemness, FACS analysis of 
CD133/CD44 double positive population was performed. After 48h hours, 
Rimonabant significantly and strongly reduces CD133/CD44 double positive 
HCT116 cells (fig. 15a). Together with CD44, Lgr5 is Wnt-regulated genes, 
CSCs markers specifically associated to 5-FU chemoresistance in colon cancer 
patients (Hsu et al, 2013). In parallel with reduction of CD133 and CD44 
expression, Rimonabant reduces Lgr5 expression (fig. 15b), suggesting its 
potential role in cancer stemness control.  
     
 Despite in the last decades great advances has been obtained in cancer 
management, the complete eradication is still an open challenge. Relapses 
onset is largely attributed to the presence of chemoresistant CSCs, refractory  
Figure 15. a FACS analysis of CD133-PE/CD44-FITC double stained HCT116 cells 
after treatment for 48h with SR 10µM. b Western blot analysis of  CD44 and  LGR5 in 
total protein lysates from HCT116 cells. Data are representative of at least three 










Figure 16. a MTT assay performed in HCT116 cells treated with indicated concentrations 
of SR or 5-FU alone or in combination; data are expressed as means ± SD of 3 
independent experiments performed in triplicate and reported as percentage vs the vehicle 
control (**P < 0.01 vs control). b Combination Index plot (Fa-CI plot) obtained with 
Compusyn software entering the Fraction affected (Fa) at each dose of the drugs alone or 
in combination, at constant ratio, in three independent experiments (upper) and Fa-CI table 
from Compusyn related to experimental points (lower). c upper, Compusyn Dose 
Reduction Index plot (Fa-DRI); lower, Fa-DRI table for experimental points, for each drug 









to conventional chemotherapy (Zeuner et al, 2014). To evaluate if Rimonabant 
could ameliorate the antitumor effects of 5-Fluorouracil, one of the most used 
chemotherapeutics in colon cancer treatment, MTT assay was performed in 
combined treatments, in dose-dependent manner.  
Specifically, 24h co-treatments of Rimonabant with dose range of 0,16 - 10 
µM in combination with 5-FU with dose range of 0,4 - 25 µM, were 
performed in HCT116 cells. As indicated in figure 16a, combination of this 
two compunds significantly ameliorates the effect of 5-FU, starting from non-
active single doses of 0,16 µM and 0,4 µM of Rimonabant and 5-FU, 
respectively. Moreover, analysis of pharmacologic interaction with Compusyn 
software, reported a Combination Index ≤ 1, starting from 0,16 µM and 0,4 
µM and until 5 µM and 12,5 µM of Rimonabant and 5-FU, respectively, 
indicating a synergistic interaction (fig. 16b). In figure 15c, Dose Reduction 
Index of both compounds obtained with Compusyn software, are reported for 
each combination.  
 
3.9 Cell death induction in colon cancer stem cell line GTG7.  
As described in materials and methods, GTG7 cells are patients derived 
spheroidal cultures, stable transfected with Wnt-TOP-GFP reporter. Since Wnt 
activity correlates with cancer stemness (Vermeulen et al, 2010), in this 









), thereby taking 
into account of tumor heterogeneity. To evaluate Rimonabant-mediated cell 
death induction on CSCs, caspase-3 activity was measured with FACS-based 
CaspGlow active staining kit, gating on 10% of TOP-GFP
high 
(CSCs) and, in 
same experiment, on 10% TOP-GFP
low
 (differentiated tumor cells). FACS 
analysis of GTG7 cells treated for 24h with Rimonabant 5-10-15 or 20 µM 
revealed that Rimonabant significantly activates caspase-3 both in Wnt
low
 
differentiated tumor cells (in a more pronounced manner) and in Wnt
high










Figure 17. Representative histograms (upper panel) and bar histogram (lower) of Caspase 3 
activation in GTG7 cells treated for 24h with Rimonabant or veichle alone at the indicated 









) cells, corresponding to 
differentiated tumor cells. Data are expressed as mean ± SD of at least three independent 









 CSCs, in a dose-dependent manner, starting from 10 µM (fig. 17). This 
result reveals for the first time the ability of Rimonabant to induce cell death 
mechanisms in chemoresistant and high tumorigenic colorectal CSCs 
population. Furthermore, in a same manner, a conspicuously DNA 
fragmentation supports Rimonabant-mediated cell death induction in GTG7 
(fig. 18). 
 
3.10 Reduction of CSCs survival in long-term cultures. 
Given to their chemoresistance and high tumorigenicity, CSCs are certainly 
associated to tumor recurrence (Zeuner et al, 2010). Thus, development of 
Figure 18. Representative histograms and images (upper panel) and bar histogram (lower) of 
DNA fragmentation amount in PI-stained GTG7 cells, treated for 24h with Rimonabant or 
veichle alone at the indicated doses. Data are expressed as mean ± SD of at least three 









novel strategies to overcome CSCs long-term survival and spreading is 
essential for complete eradication.  
Figure 19. upper panel, Representative images of GTG7 clones after 24h of treatment 
with Rimonabant (or veichle control) starting from day 0 (corresponding to the end of 
treatments) and until day 13. Growth of spheroidal clones was monitored in three 
independent experiments in triplicate. Lower, Cell Titer Blue (CTB) colorimetric assay in 
GTG7 treated for 24h, as described. Data are expressed as mean ± SD of at least three 









In the light of results obtained, Rimonabant effects on GTG7 clonogenicity 
was performed. To this aim, GTG7 were treated with dose range 5-20 µM for 
24h. At the end of treatments Rimonabant was re moved from culture medium. 
The cells from each replicate were collected and seeded as spheroids in non-
adherent conditions. Through Cell Titer Blue colorimetric assay, viability of 
spheroids was monitored starting from day 0 (which coincides with the end of 
treatments) for total 13 days. As clearly shown in figure 19, Rimonabant 
strongly reduces GTG7 survival: with 10 and 15 µM, the appearance of vital 
clones were detected only after 9 days. After 13 days, at 20 µM dose vital 
clones were not identified, suggesting a probable excessive toxicity of this 
dose. Substantially, reduction of GTG7 survival in long-term cultures supports 
Rimonabant ability of cancer stemness control. 
 
3.11 Rimonabant does not improve Oxaliplatin and 5-Fluorouracil 
effects in GTG7 cells. 
Previous results in HCT116 cell line, show that a synergistic interaction 
exists between Rimonabant and 5-FU. Since CSCs are highly chemoresistant, 





fractions. To this aim, GTG7 were pre-treated for 6h with 
Rimonabant 10 µM. At the end of pre-treatments, 25 µM of Oxaliplatin or 5-
FU were added for total 24h. As shown, at these concentrations Rimonabant 
reduces the efficacy of Oxaliplatin and produces only a slight but non-
significant improvement of 5-FU efficacy (fig. 20). Even if further 
experiments are required to establish the type of pharmacologic interaction, 


















Figure 20. Representative histograms (upper panel) and bar histogram (lower) of 
analysis of Caspase 3 activation in GTG7 cells treated with single or combined compunds 
Rimonabant 10µM, 5-FU 25µM, Oxaliplatin 25µM or veichle alone. Caspase 3 (PE 









) cells, corresponding to 
differentiated tumor cells. Data are expressed as mean ± SD of at least three independent 









3.12  Rimonabant shows no toxicity against normal colon human 
organoids. 
Encouraging results obtained in vivo, in vitro and for the first time in 
isolated primary colon CSCs, strongly suggest that Rimonabant could be a 
novel lead compound in treatment of high malignant colorectal cancer. Since 
that ideal therapeutic strategy consists of selective compounds toward cancer 
cells, with lowest toxicity against healthy tissues, evaluation of Rimonabant 
effects on normal colon was performed in wild type normal colon human 
organoids cultures.  
As described in material and methods, normal colon organoids derived 
from patients, were cultured in matrigel and treated for 24h with Rimonabant 
10, 15 and 20 µM, corresponding to the most active concentration in GTG7. 
At the end of treatments (fig 21a), for each replicate matrigel was destroyed 
and removed. Crypts were collected, disaggregate and stained with PI for 
FACS evaluation of DNA fragmentation status. Surprisingly, FACS analysis 
of cells derived from Rimonabant treated organoids showed the same percent 
of fragmented DNA compared to control organoids, also at 20 µM dose, 
suspected of extreme toxicity against GTG7 (fig 21b). Finally, we performed 
clonogenic assay on normal colon organoids. After 24h of treatments at 
indicated doses, Rimonabant was removed, crypt were collected, diluted and 
seeded again in new matrigel. Crypts were counted on day 0 (corresponding to 
end of treatments) and after 7 days. Ratio of clones number on day 7 respect to 
clones number on day 0, indicates that Rimonabant don’t reduces 
clonogenicity of wild type normal colon organoids (fig. 21c). On the other 
hand, at 15 µM dose, Rimonabant seems to induce clonogenicity. Further 
experiments are required to clarify if this last result could be due to 















Figure 21. a Representative images of normal colon human organoids cultured in matrigel and 
treated for 24h with Rimonabant or veichle alone at the indicated doses. b Analysis of DNA 
fragmentation amount in PI-stained cells derived from normal colon human organoids treated 
for 24h with Rimonabant or veichle alone at the indicated doses. c Analysis of normal colon 
human organoids clonogenicity after treatments with Rimonabant or veichle alone at the 
indicated doses. Results represents the ratio of number of clones on day 7 vs number of clones 
on day 0 (corresponding to the end of treatments). Data are expressed as mean ± SD of two 


















Despite in the last decade the improvement of colon cancer management 
increases patient’s life expectancy, eradication of high malignancy forms, then 
metastatic and drug resistant phenotypes, remain a still open challenge to 
contrast disease relapses. Thus, discovery and development of new drugs 
aimed to ameliorate therapeutic protocol for advanced malignancy are urgently 
needed.  
It has become clear that CRC is a heterogeneous disease, both at 
intratumoral and intertumoral level (Punt et al, 2016). This increases 
difficulties in its management and, therefore, development of personalized 
medicine protocols based on molecular subtype, is the best solution for an 
ideal therapy. To date, understanding of molecular mechanisms responsible for 
chemosensitivity, influences clinical decision about the use of EGFR 
inhibitors (e.g. cetuximab or panitumumab), small molecules targeting BRAF 
or combined use of tyrosine kinase (TKI) and histone deacetylase (HDACi) 
inhibitors (Hertzman Johansson & Egyhazi Brage, 2014; LaBonte et al, 2011; 
Bardelli & Siena, 2010). However, discovery and characterization of novel 
prognostic biomarkers need to be improved.  
Recently, Guinney and colleagues (2015), proposed a novel gene 
expression–based subtyping classification system for CRC. They identified 







(canonical) is the largest subgroup (about 37%) presenting Myc and Wnt 
pathway hyperactivation. This result confirmed that Wnt/-Catenin pathway 
plays a pivotal role in the onset and progression of CRC and the study of its 
intricate regulation is now emerging as a promising field to identify potential 
target of intervention for CRC treatment 
Generally, Wnt pathway seems to be cell and context specific and the Wnt 
targetome regulates several functions in the cellular context, both in healthy 
and cancer tissues (Anastas & Moon, 2013; Vlad et al, 2008). Despite the 
difficulties in the control of this complex signaling, several compounds able to 
inhibit Wnt activity are under development in anticancer therapies. In an 
ongoing clinical trial, LGK974 (also known as WNT974) porcupine inhibitor, 
which blocks the palmitoylation and secretion of Wnt ligands (Liu et al, 2013), 
is used in triple combination with LGX818 and Cetuximab in BRAFV600-
mutant metastatic CRC (#NCT02278133). Many other clinical trials are 
currently ongoing. Of note two non-steroidal anti-inflammatory drugs 
(NSAIDs) are able to inhibit Wnt signaling: sulindac, Dvl inhibitor currently 
in phase II trials and celecoxib, β-Catenin inhibitor in COX-2-dependent and –
independent manner (Takebe et al, 2015; Lee et al, 2009). Moreover, 
inhibitors of CBP/β-Catenin interaction, in particular ICG-001 and the second-
generation compound PRI-724, also received great interest. PRI-724 antitumor 
action was evaluated in phase Ib trial, in combination with FOLFOX6 protocol 
(#NCT0132405) in metastatic CRC patients.  
Intriguingly, some authors reported that cannabinoid compounds are able to 
modulate Wnt/β-Catenin pathway in cancer. Specifically, anandamide (AEA) 
activates non-canonical Wnt5-mediated signal, inhibiting cholangiocarcinoma 
growth (DeMorrow et al, 2008) and in breast cancer cells, met-F-AEA inhibits 
(TCF) responsive element activation, reduces β-catenin protein levels and 
downregulates mesenchymal markers expression (Laezza et al, 2012). 







gliomagenesis, targeting glioma stem cells and inducing their differentiation 
(Aguado et al, 2007; Nabissi et al, 2015). In addition, Sharma and colleagues 
(2014) reported that cannabis extracts with high CBD concentration, was able 
to control prostate cancer stem cells, inhibiting spheroids growth, in vitro. 
These observation strongly suggest a potential role of cannabinoids in Wnt-
related mechanisms, such as cancer stemness.  
For decades, despite some unresolved disputes, endocannabinoid system 
modulators have gained increasing attention not only for their effects against 
cancer-related symptoms (such as anti-inflammatory, pain reliever or 
antiemetic action), but also as anticancer agents in many tumour types, 
including colon cancer (Velasco et al, 2016; Maida et al, 2016). Many reports 
indicate that cannabinoid compounds are able to reduce progression of CRC in 
vivo in the azoxymethane (AOM) induced ACF model in mice and to improve 
the efficacy of chemotherapeutic drugs used in the clinical practice (Gazzerro 
et al, 2010; Santoro et al, 2009; Gustaffson et al. 2009; Izzo et al, 2008). In 
addition, Proto and colleagues, in 2010, demonstrated that increased 
availability of cannabinoids, of both exogenous and endogenous sources, in 
CRC cells induced up-regulation of CB1-receptor expression by co-
localization of PPARγ and RXRα at the promoting region and increased the 
expression of ER-β, thus suggesting a potential epigenetic modulation in 
cannabinoids-mediated antitumor effects. 
Previous works from our group reported that an antagonist/inverse agonist 
of CB1 receptor, Rimonabant is able to exert antitumor action in different 
cancer models (Ciaglia et al, 2016; Malfitano et al, 2012). Of note, In CRC 
cell lines (DLD-1, CaCo-2 and SW620 cells), Rimonabant produced mitotic 
catastrophe and modulated the expression of Cyclin B1, PARP-1, Aurora B 
and phosphorylated p38/MAPK and Chk1, improving the efficacy of 







In this work, we evaluated antitumor action of four different cannabinoids 
compounds, in high malignant human CRC cells HCT116, expressing APC 
and BRAF wild type and harboring -Catenin mutation (loss of 
phosphorylation site S45), KRASG13D and PIK3CAH1047R activating mutations 
that confers maximal resistance to Cetuximab (Jhawer et al, 2008). The most 
active compounds were met-F-AEA and in particular Rimonabant, that in our 
model was also able to induces G0/G1 accumulation and apoptosis. In the light 
of previous reports, the main goal of the project was to test the hypothesis that 
antitumor effects of both CB1 agonist and antagonist in CRC could be due to 
direct modulation of Wnt/-Catenin pathway. Inhibition of TCF/LEF reporter 
gene, highlighted for the first time the ability of Rimonabant, more than met-
F-AEA, to contrast Wnt hyperactivation in our in vitro model of colorectal 
cancer. Moreover, in HCT116 Rimonabant inhibits -Catenin nuclear 
translocation, probably because of its cytosolic destabilization, evidenced by 
the increased phosphorylation, known to be tag for proteasomal degradation. 
An indirect evidence of reduced -Catenin nuclear activity, was obtained 
analyzing expression of TCF/LEF-controlled gene products, Cyclin D1, COX-
2 and c-Myc, well know genes involved in CRC carcinogenesis. Results 
showed that in HCT116 cells Rimonabant strongly reduces expression of these 
genes. Interestingly, as described above COX-2 inhibitors (e.g. NSAIDs 
drugs) are currently under investigation as Wnt/-Catenin pathway inhibitors. 
Transcription of COX-2 gene is controlled by several consensus sequences in 
the promoter region, including TFC/LEF responsive elements. Moreover, 
prostaglandin E2 (PGE2), a COX-2 product, reduces -Catenin 
phosphorylation and increases its nuclear localization. Finally, Celecoxib, was 
found to inhibit both c-Met and Wnt activity in CRC cells (Castellone et al, 
2005; Tuynman et al, 2008; Nuñez et al, 2011). Some results showed that the 







expressing moderate or high COX-2 levels but not of cells with very low 
COX-2 expression. In these models, the AEA induced cell death seems 
mediated via its metabolism by COX-2, rather than degradation into 
arachidonic acid and ethanolamine (Patsos et al, 2005). This allow us to 
speculate that Rimonabant-mediated inhibition of Wnt signaling could be 
ascribable not only to direct inhibition of CB1 receptor, but probably to other 
CB1-independent mechanisms, such as COX-2 inhibition. Of course, further 
investigations will clarify this hypothesis.  
As discussed, our principal model HCT116 cell line, arbor mutation of -
Catenin gene (loss of phosphorylation site S45), rather than APC. Since that 
this genotype represents only a small percentage of CRC, we analyzed 
Rimonabant effects on Wnt signaling in three other CRC in vitro models, 
aimed to establish if the observed effects were related to specific genotype. 
We chose SW48 cells, displaying genetic profile similar to HCT116, 
harboring loss of phosphorylation site of -Catenin, and presenting APC wild 
type gene. Moreover, both HCT116 and SW48 cells are highly insensitive to 
some chemotherapeutic drugs. In human CRCs, the loss of function of APC is 
mainly ascribable to truncated mutations rather than hypermethylation of the 
APC gene promoter (Zhang et al, 2009). Several reports indicated that APC 
regulates -Catenin degradation complex in different way and cancer-specific 
APC truncation did not prevent completely -Catenin phosphorylation, but 
inhibit -Catenin ubiquitination and degradation, with final effect of still 
reduced nuclear translocation (Wang et al, 2014; Yang et al, 2006). Thus, we 
used DLD1 and SW620 cell lines, -Catenin wild type cells, presenting APC 
truncation. In addition, they are more sensitive than SW48 and HCT116 to 
chemotherapeutics. As expected, analysis of -Catenin phosphorylation status, 
revealed that the strongest and persistent induction arise in -Catenin mutant 







inhibition of canonical Wnt signal through plasma membrane was found. In 
addition, only in HCT116 cell line, Rimonabant increases the activity of the 
non-canonical Wnt/-Catenin pathway through up-regulation of Wnt5A and 
ROR2 receptor and activation of CaMKII. Even if further investigation are 
needed to explain why non-canonical pathway activation occurred only in 
HCT116 cells, the results seem also suggest that Rimonabant could be able to 
upregulate the expression of both APC and Wnt5A. 
In the light of the role of APC truncation in CRC, as described above, the 
finding that Rimonabant reduces the expression of the Wnt-regulated genes, 
Cyclin D1, COX-2 and c-Myc with similar trend in all the models used, it is 
not so surprising. Indeed, this result, it’s in agreement with reports from Wang 
and colleagues (2014), which indicate that in DLD1 and SW620 cells, were 
APC truncation occurs, the weak induction of -Catenin phosphorylation, did 
not ruled out its reduced nuclear activity. 
Encouragingly, our data demonstrated for the first time the in vivo efficacy 
of Rimonabant in reducing the HCT116 xenograft growth. In tissue specimens 
from xenografts, despite the awaited tumor samples heterogeneity, the 
evidence of an increased expression of p-β-Catenin and down-regulation of c-
Myc and Cyclin D1 seems to represent a very encouraging validation of the 
Rrimonabant efficacy in tumors harboring β-Catenin mutation. These data 
show, for the first time, enough direct evidence of the inhibition of the 
canonical Wnt/β-Catenin pathway and of β-Catenin target genes by 
cannabinoid compounds in human CRC. 
Results from cell-free Inverse virtual screening study, suggested that 
Rimonabant shows high affinity to HAT catalytic domain of p300. Since p300 
play a key role in -Catenin transcriptional machinery, this finding 
corroborated our hypothesis of a Rimonabant-mediated transcriptional 







compound. Our results, confirmed that Rimonabant inhibits HAT-p300 
activity, as also evidenced from reduced histone H3 and histone H4 
acetylation, in particular in HCT116 cells. 
Discovery of this unexplored novel role for Rimonabant, takes significance 
that is even more important if we consider some aspects: to date, selective 
p300 inhibitors were not identified, but in CRC both CBP-specific inhibitor 
(ICG-001) and p300/CBP non-selective inhibitor (C646) inhibit Wnt 
signaling. Of note, in HCT116 cells these two compounds regulate Wnt-target 
genes (such as c-Myc and Cyclin D1) with similar trend (Gaddis et al, 2015). 
Some evidence indicate that specific p300- or CBP-β-Catenin interaction, may 
differentially regulate apoptosis and proliferation of colon cancer cells 
(Bordonaro & Lazarova, 2016; Lenz & Khan, 2014). However, the precise 
differences between p300- or CBP-mediated Wnt-regulation is a still open 
question and further investigation will help to elucidate CBP- or p300-
mediated changes in colonic neoplastic phenotype. Despite this, as witnessed 
by the fact that they are under investigation in ongoing clinical trials, 
p300/CBP inhibitors remain promising compounds in colon cancer treatment, 
able to inhibit Wnt signalling and, in addition, to control cancer stemness in 
several tumor types (Takebe et al, 2015). 
Supported by encouraging results, as next step we tested the hypothesis that 
Rimonabant could control colon cancer stemness. As widely reported, Wnt 
and c-Myc hyperactivity, contrasted by Rimonabant, are clearly markers of 
CSCs. However, tumor heterogeneity implies that only a small subset of tumor 
cells retains tumorigenic ability, while a largest part differentiated in tumor 
cells that lost the ability to initiate cancer. The so-called CSCs, are certainly 
associated to tumor recurrence given their high chemoresistance to the large 
part of chemotherapeutics (Zhao, 2016; Paldino, 2014; Zeuner et al, 2014; 
Todaro et al, 2010). Wnt hyperactivation in CSCs is associated with specific 







findings, we found that Rimonabant reduces CD133/CD44 HCT116 double 
stained subpopulation and downregulates Lgr5 expression. As CD44, Lgr5 is 
Wnt-regulated gene associated to 5-FU chemoresistance in colon cancer 
patients (Hsu et al, 2013). Gazzerro and colleagues (2010) demonstrated that 
Rimonabant ameliorates Oxaliplatin effect in CRC cell, in vitro. Here we 
showed that this cannabinoid compound, in parallel with Lgr5 reduction in 
HCT116, was able to produce strong synergistic interaction with 5-
Fluorouracil, to date one of the widely used drugs in CRC management.  
Vermeulen and colleagues, in 2010, developed an in vitro model of primary 
CSCs in which it’s possible to take into account of tumor heterogeneity, 
monitoring Wnt activity. In this model, Rimonabant confirmed its ability to 
control cancer stemness, inducing strongly activation of caspase 3, then cell 
death, both in differentiated tumor cells (characterized by Wnt-low activity) 
and in CSCs (defined as Wnt-high active cells). Certainly, this result indicated 
that Rimonabant is not selective toward CSCs, but the observation of a strong 
reduction of CSCs survival in long-term cultures, allow us to confirm for the 
first time Rimonabant ability in colon cancer stemness control. Unfortunately, 
in primary CSCs, Rimonabant did not resulted able to ameliorate nor 
Oxaliplatin neither 5-Fluorouracil effects. Probably, this latter result, could be 
due to the high chemoresistance of CSCs. 
Since Wnt/β-Catenin pathway regulates both normal and cancer tissues 
homeostasis, its targeting in CSCs could be a risk against normal tissues. For 
this reason, safely eradication of CSCs and, generally, of cancer cells, need to 
be improved by discovery of selective drugs. In recent years, development of 
ex vivo cultures “organoids”, in which material from patients can be cultured 
in vitro, retaining both architecture and heterogeneity of original tissue, 
pioneered the better understanding of both tumor biology and normal tissue 
homeostasis. These models are currently used for a wide spectrum of 







but also drug discovery (Ohta & Sato, 2014; Leushacke & Barker, 2014). In 
our previous work, we reported the antiproliferative effect of Rimonabant in 
glioma cell line and primary cells from patients, without significant toxicity in 
Normal Human Astrocyte (NHA), thus demonstrating moderate selectivity 
toward glioma cells, in vitro (Ciaglia et al, 2015). Here, for the first time, we 
demonstrated that in normal colon human organoids (wild type organoids that 
recapitulate, with high fidelity, normal colon epithelium) Rimonabant did not 
shows toxicity or clonogenicity reduction in normal cells, also at higher doses. 
To date, many reports tried to elucidate distribution of receptors, ligands and 
enzymes of endocannabinoid system in the gut. While CB2 receptor shows 
relevant role in mucosal immunity, being expressed prevalently on intestinal 
macrophages, CB1 receptor seems to be expressed in smooth muscle, 
submucosal myenteric plexus and normal human colon (Wright et al, 2005). 
The intricate regulation of this system seems to be contest- and cell-specific 
and may totally differ depending on patho-physiological conditions, but the 
exact regulation must still be clarified to optimize clinical use of specific 
cannabinoid compounds. Some authors reported that acute administration of 
Rimonabant (3 and 5.6 mg/kg dose), increases gastrointestinal motility, 
diarrhoea and nausea, in dose-dependent manner. However, Carai and 
collegues (2004) demonstrated that in mice, after initial induction of intestinal 
peristalsis, tolerance mechanisms occur (Izzo et al, 2010; Carai et al, 2004). Of 
course, since normal colon organoids contain all cell type of intestinal crypt 
and villus compartments (e.g. Lgr5+ niche stem cells, goblet cells, Paneth cells 
etc.) (Leushacke & Barker, 2014), with these results we cannot establish if 
Rimonabant influences differentiation or, generally, homeostasis of normal 
epithelium, in cell-specific manner. Thus, additional experiments would be 
needed to deepen this aspect. 
Overall, emerging results from this work depicted a completely novel and 







Described results allow us to candidate Rimonabant as a novel lead 
compound, able to control, in vitro and in vivo, Wnt/β-Catenin pathway with 
both direct inhibition of canonical signaling in β-Catenin mutant CRC cells 
and through p300 HAT activity inhibition. For the first time Rimonabant was 
reported to be an epigenetic modulator in CRC, able to eradicate colon CSCs 
population. Finally, our preliminary results on normal colon human organoids, 
seems to suggest Rimonabant selectivity toward cancer cells.  
Ongoing experiments will help us to clarify and to dissect the mechanisms 
and the selective targets of the Rimonabant-mediated epigenetic effects. . 
Moreover, since obtained results in GTG7 cells seems to be promising, we 
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